MP09-06 administration of daily 5MG tadalafil improves NOT only lower urinary tract symptoms BUT also vessel endothelial function in patients with benign prostatic hyperplasia
Abstract
You have accessJournal of UrologyBenign Prostatic Hyperplasia: Medical & Non-surgical Therapy1 Apr 2017MP09-06 ADMINISTRATION OF DAILY 5MG TADALAFIL IMPROVES NOT ONLY LOWER URINARY TRACT SYMPTOMS BUT ALSO VESSEL ENDOTHELIAL FUNCTION IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA Toshiyasu Amano, Takahiro Kishikage, and Tetsuya Imao Toshiyasu AmanoToshiyasu Amano More articles by this author , Takahiro KishikageTakahiro Kishikage More articles by this author , and Tetsuya ImaoTetsuya Imao More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.314AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Tadalafil is a promising phosphodiesterase (PDE) 5 inhibitor for erectile dysfunction (ED) treatment. Daily low dose (5mg) of tadalafil is also applied for the treatment of male lower urinary tract symptoms (LUTS) associated with benign prostate hyperplasia (BPH). PDE5 inhibitors induce relaxation of smooth muscle cells in urethra, prostate, bladder neck and blood vessels. The aim of this study is to investigate the efficacy of tadalafil for vessels endothelial function, besides male LUTS symptoms in patients with BPH. METHODS The Institutional Review Board (IRB) had approved this clinical study, and informed consents have been obtained from 70 BPH patients. (1) The male LUTS parameters such as international prostate symptom score (IPSS), overactive…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.